Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,506.48
(
-1.51%
)
US TECH 100
23,486.80
(
-0.99%
)
Dow Jones
45,577.47
(
-0.96%
)
Brent Oil
106.93
(
2.39%
)
Bitcoin
70,677.00
(
1.11%
)
News Focus
News Focus
Post# of 257264
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122806
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: iwfal post# 146431

Wednesday, 10/31/2012 7:51:49 PM

Wednesday, October 31, 2012 7:51:49 PM

Post# of 257264
BMY’s new phase-3 Lambda trial in genotype-1b is unusual insofar as it has two variables: Lambda + Daclatasvir + ribavirin vs Pegasys + Incivek + ribavirin:

http://clinicaltrials.gov/ct2/show/NCT01718158

If the former arm outperforms on safety or effcacy, it won’t be clear whether to attribute the disparity to Lambda vs Pegasys or to Daclatasvir vs Incivek.

In any event, it may take a long time to enroll this trial.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today